Upcoming events – Atara and Aslan await validating results

While Atara investors fret over problems like the repeated delays to the group’s cancer cell therapy Tab-cel, and its C-suite overhaul, they have an important clinical readout to look forward to: by the end of the year ATA188, an allogeneic T-cell immunotherapy, will generate efficacy data in progressive multiple sclerosis.